New Study Published in JCO Precision Oncology Features Data

SALT LAKE CITY, Nov. 03, 2022 (GLOBE NEWSWIRE) — Myriad Genetics, Inc., (NASDAQ: MYGN), a frontrunner in genetic testing and precision medication, introduced right now JCO Precision Oncology has printed a examine¹ that highlights the event and validation of a breast most cancers polygenic threat rating (PRS) for girls of all ancestries.

“PRS is one of the most powerful risk prediction tools in the field of breast cancer, and until recently a validated model had not been available to assess women of all ancestries,” stated Dr. Holly Pederson, Director of Medical Breast Services at Cleveland Clinic. “Our new methodology provides a framework for a recalibrated PRS that delivers a personalized genomic breast cancer risk assessment to all women.”

The examine — first introduced in an oral presentation on the 2021 ASCO Annual Meeting by Dr. Peterson – examined knowledge from greater than 275,000 ladies of numerous ancestral backgrounds to validate a novel methodology for assessing breast most cancers PRS by utilizing ancestry-informative genetic markers.

Results confirmed the brand new methodology of threat scoring was extra correct for girls of all ancestries, indicating that weighting threat based mostly on genetic ancestry will make it attainable to ship extra dependable outcomes to all ladies. Myriad has already integrated the enhancement into the business providing of its MyRisk™ Hereditary Cancer Test with RiskRating^®.

RiskRating is the primary threat prediction mannequin that mixes a PRS validated for girls of all ancestries with scientific and organic variables. It supplies a five-year and lifelong threat evaluation of creating breast most cancers for girls who qualify for MyRisk.

“The findings represent an important step forward to improve patient outcomes by expanding access and reducing healthcare disparities in genetic testing and breast cancer risk assessment,” stated Thomas Slavin, MD, Chief Medical Officer, Myriad Genetics. “More women will be able to benefit from knowing their genomically informed risk of developing breast cancer and work with their physicians on how to best manage that risk.”

^{1 Hughes et al. JCO Precision Oncology 2022 (https://ascopubs.org/doi/abs/10.1200/PO.22.00084)}

About Myriad Genetics
Myriad Genetics is a number one genetic testing and precision medication firm devoted to advancing well being and well-being for all. Myriad develops and provides genetic checks that assist assess the danger of creating illness or illness development and information remedy selections throughout medical specialties the place genetic insights can considerably enhance affected person care and decrease healthcare prices. Fast Company named Myriad among the many World’s Most Innovative Companies for 2022. For extra data, go to www.myriad.com.  

Myriad, the Myriad emblem, BRACAnalysis, BRACAnalysis CDx, Colaris, Colaris AP, MyRisk, Myriad MyRisk, MyRisk Hereditary Cancer, MyChoice CDx, Prequel, Prequel with Amplify, Amplify, Foresight, Precise, FirstGene, Health.Illuminated., RiskRating, Prolaris, GeneSight, and EndoPredict are logos or registered logos of Myriad Genetics, Inc. © 2022 Myriad Genetics, Inc. All rights reserved. 

Safe Harbor Statement
This press launch incorporates “forward-looking statements” inside the that means of the Private Securities Litigation Reform Act of 1995, together with statements relating a breast most cancers polygenic threat rating for girls of all ancestries and the advantages for girls of understanding their genomically knowledgeable threat of creating breast most cancers. These “forward-looking statements” are administration’s expectations of future occasions as of the date hereof and are topic to identified and unknown dangers and uncertainties that would trigger precise outcomes, circumstances, and occasions to vary materially and adversely from these anticipated. Such components embrace these dangers described in the corporate’s filings with the U.S. Securities and Exchange Commission, together with the corporate’s Annual Report on Form 10-Ok filed on February 25, 2022, in addition to any updates to these threat components filed sometimes in the corporate’s Quarterly Reports on Form 10-Q or Current Reports on Form 8-Ok.

Media Contact:
Megan Manzari
(385) 318-3718
[email protected]

Investor Contact:
Matt Scalo
(801) 584-532
[email protected]